Skip To Main Content
Andrew Chin on Muck Rack

Andrew Chin

As seen in: Medium, Nature, Wiley Online Library, Genius, Libération, MDPI, People, Sports Illustrated, Taylor & Francis Online, Vanity Fair and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

AI and Alpha: Why Technology Alone Won’t Be Enough

|
By Andrew Chin
| VettaFi Advisor Perspectives Verified
AI may be the next big alpha engine—but access alone won’t create a lasting edge. Artificial intelligence is a transformative new technology, but we believe that it’s likely to follow a familiar pattern. From spreadsheets to the internet, innovations have historically given early adopters an edge—for a time. In our view, the ability to maintain that advantage depends much more on how effectively an asset manager integrates it throughout the organization.
Open in Who Shared Issue with article?

Citizen Science for Sharks and Rays: Evaluating iNaturalist Records to Document Elasmobranch Diversity and Occurrence in the Mediterranean Sea

|
By Andrew Chin, Tina Corradi, Kristy Potgieter
| Wiley Online Library Verified
1 Introduction There are 1147 species of elasmobranchs (sharks and rays) widespread in waters worldwide (Dulvy et al. 2021), occupying both coastal and open waters. Owing to their wide diversity in form, size and ecological distribution, elasmobranchs fulfil broad ecological roles, from regulating prey populations to facilitating nutrient transport and enhancing ecosystem resilience (Dedman et al. 2024).
Open in Who Shared Issue with article?

The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart

|
By Feng Jiang, Antoine Diez, Juncheng Yao, Kelsey H. Fisher-Wellman, Richard D Lutze, Logan Kirkland, Ju Youn Beak, Mansi Goyal, Raghu Nagalingam, Samantha Morrissey, Peyton B. Sandroni, Wei Huang, Julian D. Bailon, Melissa A. Schroder, Lars Albrecht, Ethelyn Ofei, Andrew Chin, Thomas Green, Joseph McClung, McLane Montgomery, James Hagen, Brett Chrest, Edziu Franczak, Raphael T. Aruleba, Polina Krassovkaia
| Science Magazine Verified
Abstract INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS Acknowledgments Supplementary Materials REFERENCES Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Trametinib (Trm) is a highly selective mitogen-activated protein kinase kinase (MEK) inhibitor that potently and persistently abrogates extracellular signal–regulated kinase 1/2 activation.
Open in Who Shared Issue with article?
See all 91 licensed articles (102 Total)